Maurizi Niccolo', Faragli Alessandro, Imberti Jacopo, Briante Nicolò, Targetti Mattia, Baldini Katia, Sall Amadou, Cisse Abibou, Berzolari Francesca Gigli, Borrelli Paola, Avvantaggiato Fulvio, Perlini Stefano, Marchionni Niccolo', Cecchi Franco, Parigi Gianbattista, Olivotto Iacopo
Referral Center for Cardiomyopathies, Careggi University Hospital, Florence, Italy.
Center for International Cooperation, University of Pavia, Italy.
Int J Cardiol. 2017 Jun 1;236:249-252. doi: 10.1016/j.ijcard.2017.02.027. Epub 2017 Feb 10.
MHealth technologies are revolutionizing cardiovascular medicine. However, a low-cost, user-friendly smartphone-based electrocardiograph is still lacking. D-Heart® is a portable device that enables the acquisition of the ECG on multiple leads which streams via Bluetooth to any smartphone. Because of the potential impact of this technology in low-income settings, we determined the accuracy of D-Heart® tracings in the stratification of ECG morphological abnormalities, compared with 12-lead ECGs.
Consecutive African patients referred to the Ziguinchor Regional Hospital (Senegal) were enrolled (n=117; 69 males, age 39±11years). D-Heart® recordings (3 peripheral leads plus V5) were obtained immediately followed by 12 lead ECGs and were assessed blindly by 2 independent observers. Global burden of ECG abnormalities was defined by a semi-quantitative score based on the sum of 9 criteria, identifying four classes of increasing severity.
D-Heart® and 12-lead ECG tracings were respectively classified as: normal: 72 (61%) vs 69 (59%); mildly abnormal: 42 (36%) vs 45 (38%); moderately abnormal: 3 (3%) vs 3 (3%). None had markedly abnormal tracings. Cohen's weighted kappa (k) test demonstrated a concordance of 0,952 (p<0,001, agreement 98,72%). Concordance was high as well for the Romhilt-Estes score (k=0,893; p<0,001 agreement 97,35%). PR and QRS intervals comparison with Bland-Altman method showed good accuracy for D-Heart® measurements (95% limit of agreement ±20ms for PR and ±10ms for QRS).
D-Heart® proved effective and accurate stratification of ECG abnormalities comparable to the 12-lead electrocardiographs, thereby opening new perspectives for low-cost community cardiovascular screening programs in low-income settings.
移动健康技术正在彻底改变心血管医学。然而,一种低成本、用户友好的基于智能手机的心电图仪仍然缺乏。D-Heart®是一种便携式设备,能够采集多导联心电图,并通过蓝牙传输到任何智能手机。由于这项技术在低收入环境中的潜在影响,我们将D-Heart®记录与12导联心电图进行比较,确定其在心电图形态异常分层中的准确性。
连续纳入转诊至济金绍尔地区医院(塞内加尔)的非洲患者(n=117;69名男性,年龄39±11岁)。立即获取D-Heart®记录(3个外周导联加V5),随后进行12导联心电图检查,并由2名独立观察者进行盲法评估。心电图异常的总体负担通过基于9项标准总和的半定量评分来定义,确定了四类严重程度逐渐增加的情况。
D-Heart®和12导联心电图记录分别分类为:正常:72例(61%)对69例(59%);轻度异常:42例(36%)对45例(38%);中度异常:3例(3%)对3例(3%)。没有人有明显异常的记录。科恩加权kappa(k)检验显示一致性为0.952(p<0.001,一致性为98.72%)。Romhilt-Estes评分的一致性也很高(k=0.893;p<0.001,一致性为97.35%)。PR和QRS间期与Bland-Altman方法的比较显示D-Heart®测量具有良好的准确性(PR的95%一致性界限为±20ms,QRS为±10ms)。
D-Heart®被证明在心电图异常分层方面有效且准确,与12导联心电图相当,从而为低收入环境中的低成本社区心血管筛查项目开辟了新的前景。